The range of products covers cephalosporins, carbapenems and oncology drugs, intravenous products, vials/lyophilized injectables, pre-filled syringes, hormones, ampules and biological products. These are manufactured in facilities certified as EU-GMP, WHO-GMP, ISO 9001, ISO 14001 & ISO18001, Ukrainian Columbian, Uganda, Zimbabwe, Syrian and European GMP compliant.
The three manufacturing units are located in Germany and Panchkula and Baddi in India. The Baddi unit has a manufacturing capacity of 30 million vials Ciphelosporine p.a. and 10 million vials Oncologicals p.a. The company started its sixth and last phase of the Rs 1,500 million expansion project in January 2008 including the state-of-the-art hi-tech research facility Venus Medicine Research Center in Baddi with provision for eight dedicated plants manufacturing injectible formulations. Recently in March 2008, the company filed its 7th patent application with the Indian Patent Office for an antibiotic for the treatment of bacterial/multi-bacterial infections in children and was set to launch an innovative therapy for APE/cystis fibrosis patients after completion of the multi-centered phase II clinical trials.
Marketing tie-ups are in place with Indian pharmaceutical companies like Ipca Laboratories, Elder Pharmaceuticals, and many others. The company has inked an agreement with Pharma Match R&D, based in Amsterdam, Netherlands for jointly preparing, registering and marketing an EU E-CTD Dossier for a latest generation Carbapenem injectable. Several patent cooperation treaty applications have been filed and a licensing agreement signed with the University of Illinois, USA for its patent technology for detection of tumors by imaging. The company exports directly to Nepal, Yemen, Ukraine and Sri Lanka. It has tie-ups with multinational concerns for indirect exports to CIS and other countries. The registered office is located at SCO 39, Sector 26, Madhya Marg, Chandigarh-160019.